Pharma Major Lupin has received tentative approval for its Olmesartan Medoximil Tablets, 5 mg, 20 mg and 40 mg from the United States Food and Drug Administration (USFDA) to market a generic version of Daiichi Sankyo Inc’s Benicar Tablets, 5 mg, 20 mg and 40 mg. The company’s Olmesartan Medoximil Tablets are the AB rated generic equivalents of Daiichi Sankyo Inc’s Benicar Tablets. Olmesartan Medoximil Tablets are indicated for the treatment of hypertension, along or with other antihypertensive agents to lower blood pressure. Benicar Tablets had US sales of $1.06 billion (IMS MAT September 2016).
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.
